ascopubs.org

A Novel predictive probability algorithm to determine risk for malignancy between uterine ...

A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707). This is an ASCO ...